Press Releases FibroGen, Inc.

Equities

FGEN

US31572Q8087

Real-time Estimate Cboe BZX Other stock markets 01:23:37 09/05/2024 am IST			5-day change	1st Jan Change
1.135 ^USD	-17.15%		-2.14%	+29.19%

07/05	Top Premarket Gainers	MT
06/05	Transcript : FibroGen, Inc., Q1 2024 Earnings Call, May 06, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS	05:44pm	AQ
FibroGen : Corporate Presentation – May 2024	05:26am	PU
FibroGen to Participate in Upcoming Investor Conferences	07/05	AQ
FibroGen: Q1 Earnings Snapshot	07/05	AQ
FibroGen Reports First Quarter 2024 Financial Results	07/05	AQ
FibroGen to Report First Quarter 2024 Financial Results	29/04	AQ
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting	25/04	AQ
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer	03/04	AQ
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference	26/03	AQ
FibroGen : Corporate Presentation – March 2024	19/03	PU
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer	11/03	AQ
FibroGen : Corporate Presentation – March 2024	06/03	PU
FibroGen: Q4 Earnings Snapshot	27/02	AQ
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results	27/02	AQ
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea	27/02	AQ
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results	20/02	AQ
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024	05/02	AQ
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer	25/01	AQ
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	27/12	BU
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting	10/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases FibroGen, Inc.

Equities

FGEN

US31572Q8087

Press Releases

Filters